CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation (CD45RADLIPx)

CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study

The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:

Does this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?

Study Overview

• Status: Not yet recruiting
• Conditions: Hematologic Malignancy; Haplo-identical HCT
• Intervention / Treatment: Biological: CD45RA-depleted DLI

Detailed Description

Following allogeneic hematopoietic stem cell transplantation (allo-HSCT), delayed immune reconstitution and long-term use of immunosuppressants leave patients in a prolonged immunocompromised state, predisposing them to various infections, which represent a leading cause of transplant-related mortality. Conventional antiviral agents such as ganciclovir and valganciclovir are associated with hematologic toxicities, including neutropenia and anemia, potentially complicating post-transplant management. Meanwhile, newer antivirals such as cidofovir have not yet been approved in China, limiting patient access. Antiviral cell therapies, represented by virus-specific T cells (VSTs), are expensive and require prolonged culture periods. Therefore, there is an urgent need to identify effective strategies to prevent viral infections after HSCT, especially in high-risk patients.

Previous studies suggest that adoptive donor lymphocyte infusion (DLI) can facilitate immune reconstitution; however, the CD45RA-positive naïve T cells contained in conventional DLI are a major cause of graft-versus-host disease (GvHD). By depleting naïve T cells from donor lymphocytes ex vivo while retaining donor memory T cells (Tm), it is possible to promote post-transplant immune reconstitution without increasing the risk of GvHD. This study plans to conduct a prospective, multicenter, single-arm pragmatic clinical trial. Using the CliniMACS® cell selection system, we will selectively deplete CD45RA-positive T cells ex vivo and infuse the CD45RA-depleted donor lymphocytes (i.e., CD45RA Depleted DLI) to prevent viral infections in high-risk patients after transplantation. The efficacy, safety, and impact on post-transplant immune reconstitution of this regimen will be evaluated.

Primary objective: To evaluate the efficacy and safety of CD45RA Depleted DLI in preventing viral infections in high-risk patients after transplantation.

Secondary objective: To evaluate the impact of CD45RA Depleted DLI on immune reconstitution after transplantation.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • SH
    • Shanghai, SH, China, 200025
      • Ruijin Hospital
      • Contact: Xiaoxia Hu, MD, PhD; Phone Number: 008613795437259; Email: hu_xiaoxia@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Participants must meet all of the following criteria:

• Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).
• Presence of at least one high-risk factor for post-transplant viral infection (any of the following):
• Age ≥50 years or ≤14 years
• Non-sibling matched transplantation
• In vivo or ex vivo T-cell depletion
• Myeloablative conditioning
• Conditioning containing radiotherapy
• Second transplantation
• CMV IgG or EBV IgG donor/recipient mismatch (donor positive, recipient negative)
• History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg/kg/day)
• Availability of a suitable lymphocyte donor (see "Donor Selection Criteria").
• Adequate organ function meeting the following laboratory criteria:
• Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN
• Renal function: BUN and creatinine ≤1.25× ULN
• No cardiac dysfunction on electrocardiogram or echocardiogram
• Pulmonary function: oxygen saturation >90% without supplemental oxygen
• The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from this study:

• Active grade II-IV acute graft-versus-host disease (aGVHD)
• Active aGVHD requiring prednisone or equivalent corticosteroid >0.5 mg/kg/day
• Active viral infection
• Uncontrolled or relapsed malignancy
• Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prevention Group; Prophylactic CD45RA-depleted DLI	Biological: CD45RA-depleted DLI; CD45RA Depleted DLI by ex vivo CliniMACS® prepared from mononuclear cell leukapheresis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative Incidence of Overall Viral Infection After CD45RA-Depleted DLI	Overall viral infection is defined as the first occurrence of any qualifying viral infection or reactivation detected by quantitative PCR after the first CD45RA-DLI infusion. Viruses assessed include CMV, EBV, ADV, BKV, HHV6, JCV, and B19. A participant will be considered to have a qualifying viral event if any of the following thresholds are met: CMV DNA ≥250 IU/mL, EBV DNA ≥250 IU/mL, ADV DNA ≥1,000 copies/mL, BKV DNA ≥5,000 copies/mL, HHV6 DNA ≥1,000 copies/mL, JCV DNA ≥1,000 copies/mL, or B19 DNA ≥1,000 copies/mL. The outcome will be reported as the cumulative incidence, expressed as the percentage of participants with at least one qualifying viral infection or reactivation event during the assessment period.	Up to 3 months after the first CD45RA-depleted DLI, assessed at Days 14, 28, 60, and 90.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative Incidence of Virus-Specific Infections After CD45RA-Depleted DLI	Report cumulative incidence separately for CMV, EBV, ADV, BKV, HHV6, JCV, and B19 using the protocol-defined PCR thresholds.	Up to 3 months after first infusion
Absolute Counts of Peripheral Blood Lymphocyte Subsets as Measured by Flow Cytometry	Immune reconstitution will be assessed by flow cytometric enumeration of peripheral blood lymphocyte subsets, including CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ NK cells, and CD4+CD25+CD127- regulatory T cells.	Up to 1 year after the first CD45RA-depleted DLI
Virus-Specific T-Cell Immune Responses After CD45RA-Depleted DLI	Virus-specific immune reconstitution will be assessed by measuring virus-specific T-cell responses against CMV, EBV, ADV, BKV, B19, HHV6, and JCV using the protocol-defined virus-specific T-cell assay.	Up to 3 months after the first CD45RA-depleted DLI, assessed at Days 14, 28, 60, and 90.

Collaborators and Investigators

• Sponsor: Ruijin Hospital
• Collaborators: Shanghai Liquan Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): July 31, 2028

Study Registration Dates

• First Submitted: June 16, 2026
• First Submitted That Met QC Criteria: June 22, 2026
• First Posted (Actual): June 29, 2026

Study Record Updates

• Last Update Posted (Actual): June 29, 2026
• Last Update Submitted That Met QC Criteria: June 22, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: DLI; CD45RA
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Hematologic Neoplasms
• Other Study ID Numbers: RJ-BMT-Prophylaxis 1.0

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Outcome data will be shared via request after publication of results.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No